Baird Starts Intellia Therapeutics (NTLA) at Neutral
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $12.09 +0.58%
Rating Summary:
23 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
23 Buy, 9 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Baird analyst Jack Allen initiates coverage on Intellia Therapeutics (NASDAQ: NTLA) with a Neutral rating and a price target of $58.00.
For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.
Shares of Intellia Therapeutics closed at $42.86 yesterday.
You May Also Be Interested In
- UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
- Evercore ISI Upgrades Intellia Therapeutics (NTLA) to Outperform
- JPMorgan Starts Flutter Entertainment (FLUT) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
